Women's Health Month: Understanding How Menopause Can Impact Your Sex Life, According to a Sex & Relationships Expert
LOS ANGELES--(BUSINESS WIRE)--During menopause, women undergo significant hormonal, physical, and emotional changes, many of which can have a direct impact on sexual health and relationships. These changes are natural, but they can also be challenging, especially when they go unspoken or unsupported. In recognition of Women's Health Month, Dr. Shannon Chavez, a renowned sex and relationships expert and licensed psychologist, is shedding light on how menopause affects intimacy, and why open conversations, education, and personalized care are essential for supporting women through this stage.
"Just like puberty, this is a hormonal milestone that requires education, compassion, and the right tools. With support, this stage of life can lead to deeper self-awareness, empowerment, and even better sex.'
'Menopause is not the end of your sex life—it's the beginning of a new chapter,' says Dr. Chavez. 'But it's a chapter that comes with changes that women deserve to understand and navigate with confidence. Just like puberty, this is a hormonal milestone that requires education, compassion, and the right tools. With support, this stage of life can lead to deeper self-awareness, empowerment, and even better sex.'
Below, Dr. Chavez shares key ways menopause can affect your sex life, as well as practical guidance for navigating these changes with confidence and care:
Hormonal Shifts Can Affect Desire: A decline in estrogen and testosterone levels during menopause can lead to a noticeable drop in libido. Many women find themselves feeling less interested in sex due to hormonal changes that are entirely natural. Desire can be rekindled with intentional practices like sensate focus, sexual mindfulness, and, when appropriate, bioidentical hormone therapy.
Vaginal Dryness and Discomfort: As estrogen levels drop, the vaginal walls may become thinner, dryer, and less elastic, making intercourse uncomfortable or even painful. Vaginal dryness is one of the most common symptoms of menopause. Luckily, over-the-counter vaginal moisturizers and lubricants can improve comfort and make intimacy pleasurable again. I recommend Replens Long-Lasting Vaginal Moisturizer and Replens Silky Smooth Personal Lubricant for effective relief.
Emotional and Psychological Changes: Menopause can also bring mood swings, anxiety, sleep disturbances, and body image concerns—all of which can influence how one feels about sex and intimacy. Self-compassion, therapy, mindfulness practices, and strong communication with a partner can help women reclaim pleasure and emotional connection.
Changes in Arousal: Many women notice it takes longer to become aroused or reach orgasm during and after menopause. This is due to changes in blood flow, nerve sensitivity, and lubrication. While this can be frustrating, Dr. Chavez emphasizes that slower arousal isn't something to fear or feel ashamed of. In fact, it can lead to more intentional and deeply satisfying intimacy when couples take the time to adapt their approach to pleasure.
'A satisfying sex life during and after menopause is absolutely possible, but it starts with education and honest communication,' says Dr. Chavez. 'The more you understand your body and talk openly with your partner and healthcare provider, the more empowered you'll feel to create the kind of intimacy that truly fulfills you.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 hours ago
- Business Wire
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Business Wire
2 days ago
- Business Wire
Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit
BANGKOK--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2025 Invisalign ® Asia Pacific ('APAC') Summit held in Bangkok, Thailand, June 5 – 7, 2025. 'With more than 3 million Invisalign smiles across Asia Pacific, we know that this region sees some of the toughest clinical challenges in the field of dentistry,' said David Carr, Align executive vice president and managing director, APAC. 'The 2025 Invisalign Asia Pacific Summit underscores the importance of continued innovation and education. We are committed to working in partnership with doctors across the region in developing Invisalign treatment protocols that can help them transform smiles and change lives for even more patients.' Over three days, more than 2,000 doctors, practice team members, partners, and Align staff from across the region came together to explore the latest innovations in digital orthodontics and restorative dentistry. The summit featured over 60 expert speakers and more than 50 immersive breakout lectures and hands-on workshops, all designed to help doctors elevate clinical outcomes, streamline workflows, and grow their practices. Key topics covered include kids and teen, complex treatments, comprehensive dentistry and practice growth. 'This meeting provided us with a platform to connect with doctors across the full Asia Pacific region, encourage ongoing learning and sharing and showcase how our global innovations can support doctors in this market,' said Gigi Tsui, Align senior director, clinical, APAC. 'As we celebrate 20 million Invisalign smiles globally, including 3 million Invisalign smiles across the Asia Pacific region, it's critical that we continue to engage doctors for feedback and insights. This is fundamental to developing new innovations that meet the unique needs of doctors and patients across this region.' Attendees explored new developments across multiple interactive zones in the Innovation Hub, including: Kids and Teens: Featuring Invisalign First™, Invisalign® Palatal Expander System, and Invisalign® System with mandibular advancement featuring occlusal blocks ('MAOB'). ClinCheck® signature experience: Highlighting the 1-page Rx form (Flex Rx), preference templates, and ClinCheck ® Live Update. Comprehensive Dentistry: Showcasing iTero Lumina™ Pro dental imaging system, iTero™ intraoral scanner, Invisalign Smile Architect™, and Invisalign® Smile Video. Consumer & Branding: Demonstrating branding and tools to help doctors raise awareness of digital treatment options among patients of all ages. Clinical Excellence: Sharing clinical tools, evidence-based resources, education and insights available to doctors and staff. The summit also featured a Women Leadership session and provider recognition and lifetime achievement awardees. In addition to the core Asia Pacific Invisalign Summit, over 300 delegates across 78 universities also attended the Align APAC University Forum hosted at the renowned Chulalongkorn University in Bangkok. The forum served as a dynamic platform for cross-border collaboration and meaningful dialogue on how Align's evidence-based approach and cutting-edge innovations complements academic excellence and clinical training. Key highlights included keynote presentations by industry experts, interactive case-based discussions, resident showcases, and panels on integrating aligner therapy into university curriculum. The event also celebrated academic excellence with the APAC Case Challenge and Align research awards for APAC, while fostering peer-to-peer collaboration and inspiring the next generation of orthodontic leaders. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Business Wire
2 days ago
- Business Wire
Chemed To Report Second-Quarter 2025 Earnings July 29, 2025
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2025, on Tuesday, July 29, 2025, following the close of trading on the New York Stock Exchange. Chemed also announced developments related to second quarter earnings and full year 2025 guidance. In prior public statements, management discussed the possibility that the VITAS subsidiary could have an aggregate Medicare Cap billing limitation (Medicare Cap) related to its Florida consolidated program, excluding Tallahassee. However, as of the most recent quarterly earnings update, VITAS internal projections showed that the Florida consolidated program would end the 2025 government fiscal year ending on September 30, 2025 (2025 Cap Year) with a Medicare Cap cushion. Actual Medicare admissions in both April and May 2025 in Florida were weaker than anticipated and lower than VITAS' internal projections. As a result, VITAS now projects a Medicare Cap revenue limitation for the 2025 Cap Year of $18 million to $25 million related to the Florida consolidated program, excluding Tallahassee. The above projection includes actual results through May. Actual June results, which show better admissions than projected through the first half of the month, and actual results in the third quarter could have a significant impact on this projection. Previous guidance for 2025 earnings did not include any Florida Medicare Cap. The source of the Medicare Cap in the Florida consolidated program relates to two factors. The first factor is the 'community access' program. While community access has provided for a higher-than-average ADC growth rate and revenue growth rate at VITAS over the past two years, it adds pressure to the Medicare Cap due to patients accessing hospice care earlier in their disease trajectory. The second factor is the rate differential between the nationally determined increase in the Medicare Cap per admission and the actual reimbursement increase in our Florida consolidated programs, excluding Tallahassee, for the 2025 Cap Year. Specifically, the Medicare Cap per admission amount increased 2.9% while the Florida consolidated program reimbursement increase was 5.2%. VITAS estimates this rate differential will negatively impact the Florida consolidated program's Medicare Cap calculation by approximately $25 million for the 2025 government fiscal year, accounting for most, if not all, of the total revenue limitation discussed above. On June 20, 2025, the State of Florida announced that VITAS has received a Certificate of Need (CON) to begin operating in Pinellas County, Florida. Pinellas is the most densely populated county in Florida and has a hospice utilization rate below the state average. There were approximately 8,600 Medicare admissions to existing hospice providers in Pinellas County in 2024. Entering Pinellas County represents a significant opportunity for VITAS in 2026 and beyond for both overall growth and Medicare Cap mitigation. Based on the new start locations in Florida, primarily Marion County and Pinellas County, combined with operational changes currently being made in the Florida programs, management expects not to have any significant level of Medicare Cap revenue limitation in our Florida consolidated program for the 2026 fiscal year. This expectation assumes that the rate differential discussed above does not recur for the 2026 Cap Year. In the event that the rate differential does recur, VITAS will respond with further mitigation strategies at the outset of the 2026 Cap Year. While less financially significant than the VITAS Medicare Cap situation, during the second quarter of 2025, Roto-Rooter began to experience unexpected weakness in its residential business' demand compared to internal projections. This weakness represents a break from the trends experienced in the first quarter of 2025. Preliminary results for commercial demand in the second quarter of 2025 continue to reflect improved trends but not enough to offset the lower residential demand. Management is in the process of analyzing second quarter performance and the impact of these developments on second quarter results and on full-year 2025 guidance. A full discussion of the analysis will be included with our second quarter 2025 release and related investor conference call. Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, July 30, 2025, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed's website, Investor Relations Home | Chemed Corporation or the hosting website Participants may also register via teleconference at: Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time. A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed's website. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation ( operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed's operations, including Medicare Cap and Medicare reimbursement rates, Chemed's estimates of the effect of Medicare Cap on VITAS' revenues and future prospects, Chemed's expectations regarding VITAS' patient mix, VITAS's future prospects in Pinellas County, FL and Chemed's expectations regarding demand for Roter-Rooter's services. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed's control. Chemed's actual results and financial condition may differ materially from those indicated in the forward-looking statements included in this press release, including as a result of the risks described above and those described in the Chemed's Annual Report on Form 10-K for the year ended December 31, 2024 and in its Quarterly Reports filed in 2025. Any forward-looking statement made by Chemed in this press release are based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
